Drugs / Istaroxime
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT02772068 | Sep 2015 → Dec 2018 | congestive heart failure | Benjamin Levine | Completed | No outcome recorded |
| Phase 11 trial | ||||||
| Phase 1 | NCT02477449 | Mar → Oct 2015 | — | Lee's Pharmaceutical Limited | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05975021 | Jun 2024 → Jul 2025 overdue | cardiogenic shock | Windtree Therapeutics | Active not recruiting | No outcome recorded |
| Phase 24 trials · 3 met primary | ||||||
| Phase 2 | NCT04325035 | Sep 2020 → Sep 2024 | cardiogenic shock | Windtree Therapeutics | Completed | Met primary |
| Phase 2 | NCT02617446 | Dec 2015 → Aug 2018 | heart failure | Windtree Therapeutics | Completed | Met primary |
| Phase 2 | NCT00838253 | Jun 2009 → ? | heart failure | Debiopharm International SA | Withdrawn | No outcome recorded |
| Phase 2 | NCT00616161 | Aug 2006 → Jul 2007 | systolic heart failure | sigma-tau i.f.r. S.p.A. | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT07583446 | Jul 2026 → Dec 2028 expected | cardiogenic shock | Seismic Pharmaceuticals Operations LLC | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1 | NCT00869115 Comparator | Jun 2009 → ? | heart failure | Debiopharm International SA | Withdrawn | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2008-04-02 | Debiopharm International SA | Results Clinical Update – Debio0614 (istaroxime) in Acute Heart Failure debiopharm.com ↗ |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2008-04-02 | Debiopharm International SA | Clinical Update – Debio0614 (istaroxime) in Acute Heart Failure debiopharm.com ↗ |
| 2006-06-14 | Debiopharm International SA | The Debiopharm Group and Sigma-Tau sign R&D and commercial agreement for Istaroxime in acute heart failure syndromes debiopharm.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Istaroxime | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02772068 ↗ |
| Known as | (e,z)-istaroxime | ChEMBL registry synonym — accepted as the source's own label CHEMBL2093999 ↗ |
| Known as | Debio 0614 | “three Dose Levels of Debio 0614 (Istaroxime) as a 24-hour Constant Rate IV Infusion” NCT00869115 ↗ |
| Known as | Istaroxima | ChEMBL registry synonym — accepted as the source's own label CHEMBL2093999 ↗ |
| Known as | PST-2744 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2093999 ↗ |
| Action | Activate | “Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator” CHEMBL2093999 ↗1“Istaroxime is a novel activator of SERCA2a” NCT02772068 ↗ |
| Modality | Small molecule | — CHEMBL2093999 ↗ |
| Route | Intravenous | “0.5 microgram/kg/min IV for 6 hours” NCT00616161 ↗ |
| Target | ATP2A2 | “Sarcoplasmic/endoplasmic reticulum calcium ATPase 2 activator” CHEMBL2093999 ↗ |